Prognostic value of serum VEGF in melanoma patients

A pilot study

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Vascular endothelial growth factor (VEGF) is involved in angiogenesis. We investigated the association of VEGF serum levels (pre-treatment and follow-up) with outcome in patients with melanoma. Patients and Methods: Serum levels of VEGF in melanoma patients at diagnosis and during follow-up were analysed with enzyme-linked immunoassays. Patients were followed up with physical examination and ultrasound scans of the liver every three months and thorax X-ray annually. The VEGF serum level was evaluated six-monthly. Results: From February 1996 to February 2000, 33 patients were enrolled. Ninety-two serum blood samples were collected. Patients had a median age of 60 years (range 32-82). Twenty patients were males, 13 females. One patient presented with stage IA disease, 2 with stage IB, 11 with stage IIA, 4 with stage IIB, 8 with stage III and 5 with stage IV. Two patients were affected by uveal melanoma. The melanomas were predominantly located at the extremities or trunk (26/33). The median serum level of VEGF at diagnosis was 249 ng/ml (minimum: 9 ng/ml, maximum: 1215 ng/ml). The median survival of all 33 patients was 45.1 months. The median time-to-progression was 36.7 months. Patients with lower or higher serum VEGF values showed no statistically significant differences in survival. In contrast, high serum VEGF values were associated with shorter disease-free survival as compared with lower values (median DFS: 25 vs 60 months, p=0.048 at log-rank test). Conclusion: Our results suggest that serum VEGF could be of prognostic value in melanoma.

Original languageEnglish
Pages (from-to)4255-4258
Number of pages4
JournalAnticancer Research
Volume24
Issue number6
Publication statusPublished - Nov 2004

Fingerprint

Vascular Endothelial Growth Factor A
Melanoma
Serum
Survival
Immunoenzyme Techniques
Disease-Free Survival
Physical Examination
Thorax
Extremities
X-Rays
Liver

Keywords

  • Melanoma
  • Prognosis
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic value of serum VEGF in melanoma patients : A pilot study. / Ascierto, Paolo Antonio; Leonardi, Enrico; Ottaiano, Alessandro; Napolitano, Maria; Scala, Stefania; Castello, Giuseppe.

In: Anticancer Research, Vol. 24, No. 6, 11.2004, p. 4255-4258.

Research output: Contribution to journalArticle

@article{c06ba05e4c534b50a423c84b15668d38,
title = "Prognostic value of serum VEGF in melanoma patients: A pilot study",
abstract = "Background: Vascular endothelial growth factor (VEGF) is involved in angiogenesis. We investigated the association of VEGF serum levels (pre-treatment and follow-up) with outcome in patients with melanoma. Patients and Methods: Serum levels of VEGF in melanoma patients at diagnosis and during follow-up were analysed with enzyme-linked immunoassays. Patients were followed up with physical examination and ultrasound scans of the liver every three months and thorax X-ray annually. The VEGF serum level was evaluated six-monthly. Results: From February 1996 to February 2000, 33 patients were enrolled. Ninety-two serum blood samples were collected. Patients had a median age of 60 years (range 32-82). Twenty patients were males, 13 females. One patient presented with stage IA disease, 2 with stage IB, 11 with stage IIA, 4 with stage IIB, 8 with stage III and 5 with stage IV. Two patients were affected by uveal melanoma. The melanomas were predominantly located at the extremities or trunk (26/33). The median serum level of VEGF at diagnosis was 249 ng/ml (minimum: 9 ng/ml, maximum: 1215 ng/ml). The median survival of all 33 patients was 45.1 months. The median time-to-progression was 36.7 months. Patients with lower or higher serum VEGF values showed no statistically significant differences in survival. In contrast, high serum VEGF values were associated with shorter disease-free survival as compared with lower values (median DFS: 25 vs 60 months, p=0.048 at log-rank test). Conclusion: Our results suggest that serum VEGF could be of prognostic value in melanoma.",
keywords = "Melanoma, Prognosis, VEGF",
author = "Ascierto, {Paolo Antonio} and Enrico Leonardi and Alessandro Ottaiano and Maria Napolitano and Stefania Scala and Giuseppe Castello",
year = "2004",
month = "11",
language = "English",
volume = "24",
pages = "4255--4258",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Prognostic value of serum VEGF in melanoma patients

T2 - A pilot study

AU - Ascierto, Paolo Antonio

AU - Leonardi, Enrico

AU - Ottaiano, Alessandro

AU - Napolitano, Maria

AU - Scala, Stefania

AU - Castello, Giuseppe

PY - 2004/11

Y1 - 2004/11

N2 - Background: Vascular endothelial growth factor (VEGF) is involved in angiogenesis. We investigated the association of VEGF serum levels (pre-treatment and follow-up) with outcome in patients with melanoma. Patients and Methods: Serum levels of VEGF in melanoma patients at diagnosis and during follow-up were analysed with enzyme-linked immunoassays. Patients were followed up with physical examination and ultrasound scans of the liver every three months and thorax X-ray annually. The VEGF serum level was evaluated six-monthly. Results: From February 1996 to February 2000, 33 patients were enrolled. Ninety-two serum blood samples were collected. Patients had a median age of 60 years (range 32-82). Twenty patients were males, 13 females. One patient presented with stage IA disease, 2 with stage IB, 11 with stage IIA, 4 with stage IIB, 8 with stage III and 5 with stage IV. Two patients were affected by uveal melanoma. The melanomas were predominantly located at the extremities or trunk (26/33). The median serum level of VEGF at diagnosis was 249 ng/ml (minimum: 9 ng/ml, maximum: 1215 ng/ml). The median survival of all 33 patients was 45.1 months. The median time-to-progression was 36.7 months. Patients with lower or higher serum VEGF values showed no statistically significant differences in survival. In contrast, high serum VEGF values were associated with shorter disease-free survival as compared with lower values (median DFS: 25 vs 60 months, p=0.048 at log-rank test). Conclusion: Our results suggest that serum VEGF could be of prognostic value in melanoma.

AB - Background: Vascular endothelial growth factor (VEGF) is involved in angiogenesis. We investigated the association of VEGF serum levels (pre-treatment and follow-up) with outcome in patients with melanoma. Patients and Methods: Serum levels of VEGF in melanoma patients at diagnosis and during follow-up were analysed with enzyme-linked immunoassays. Patients were followed up with physical examination and ultrasound scans of the liver every three months and thorax X-ray annually. The VEGF serum level was evaluated six-monthly. Results: From February 1996 to February 2000, 33 patients were enrolled. Ninety-two serum blood samples were collected. Patients had a median age of 60 years (range 32-82). Twenty patients were males, 13 females. One patient presented with stage IA disease, 2 with stage IB, 11 with stage IIA, 4 with stage IIB, 8 with stage III and 5 with stage IV. Two patients were affected by uveal melanoma. The melanomas were predominantly located at the extremities or trunk (26/33). The median serum level of VEGF at diagnosis was 249 ng/ml (minimum: 9 ng/ml, maximum: 1215 ng/ml). The median survival of all 33 patients was 45.1 months. The median time-to-progression was 36.7 months. Patients with lower or higher serum VEGF values showed no statistically significant differences in survival. In contrast, high serum VEGF values were associated with shorter disease-free survival as compared with lower values (median DFS: 25 vs 60 months, p=0.048 at log-rank test). Conclusion: Our results suggest that serum VEGF could be of prognostic value in melanoma.

KW - Melanoma

KW - Prognosis

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=14944346331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944346331&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 4255

EP - 4258

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -